Arexvy vs Abrysvo
A side-by-side look at two vaccine medications advertised on TV. Informational only — not medical advice.
| US Arexvy | US Abrysvo | |
|---|---|---|
| Generic name | respiratory syncytial virus vaccine | respiratory syncytial virus vaccine |
| Drug class | Recombinant Adjuvanted Vaccine | Vaccine |
| Treats | RSV prevention in older adults | RSV prevention |
| Category | Vaccine | Vaccine |
| Manufacturer | GSK | Pfizer |
| Year approved | 2023 | 2023 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $110M | — |
| Common side effects | Injection site pain, Fatigue, Muscle pain, Headache | Injection-site pain, Fatigue, Headache, Muscle pain |
Frequently asked questions
Is Arexvy or Abrysvo better?
Neither is universally "better." Arexvy (respiratory syncytial virus vaccine) and Abrysvo (respiratory syncytial virus vaccine) are both used for vaccine, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Arexvy and Abrysvo?
Arexvy is a Recombinant Adjuvanted Vaccine made by GSK, while Abrysvo is a Vaccine made by Pfizer. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Arexvy has the larger estimated TV advertising budget of the two.